Home

  • TMA Precision Health and Dante Genomics partner to help children with rare diseases through clinical whole genome sequencing solutions

    TMA Precision Health and Dante Genomics partner to help children with rare diseases through clinical whole genome sequencing solutions

    NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, today announced its partnership with TMA Precision Health, a company on a mission to improve the lives of rare disease patients everywhere, offering clinical whole genome sequencing to rare disease patients as the first step in diagnosing and treating disease with more personalized medicine.

    “The simple act of providing a whole genome sequence is likely the single most important piece of healthcare for a patient with a rare disease, and no child or family should have to needlessly suffer because they can’t afford it,” said Joshua Resnikoff, CEO and Cofounder of TMA Precision Health. “Our mission is to bring this service to those that need it most. We are thrilled to partner with Dante Genomics to bring the highest quality genomic sequencing and interpretation services to our patients around the globe.”

    Dante Genomics will provide 30X whole genome sequencing, clinical interpretation and personalized genomic reports to TMA’s patient network of more than 3.5 million people living with rare diseases for the purposes of diagnosis.

    “There are so many people, especially children, suffering from undiagnosed rare diseases around the world, and it is this unmet need that we are working to serve every day,” said Andrea Riposati, CEO and co-founder of Dante Genomics. “We must work to end any diagnostic odyssey for these patients and reduce the time to diagnosis from years to days. Children with a rare disease, in any country, deserve the best clinical care, and TMA Precision Health is at the frontier to bring genomic driven care to the countries with the highest unmet need.”

    Dante Genomics will utilize the genomic data related to this partnership to advance internal research related to novel target identification and drug development with the ultimate goal to go beyond diagnosis to treatment of rare disease.

    TMA will incorporate the data from this partnership to continue growing the largest rare disease database in the world, with a focus on developing precision medicine solutions for rare patients everywhere.

    About TMA Precision Health
    TMA Precision Health is on a mission to provide personalized care and health equity for rare disease patients around the world. Our unique access to more than 3.5 million rare disease patients powers our ability to build on-demand comprehensive datasets of paired de-identified medical records and whole genomic sequencing and identify rare patients for clinical trials, giving our pharma partners a competitive edge when researching new insights and developing new treatments for this area of critically unmet need. For more information, please visit tmaprecisionhealth.com and follow us on LinkedIn.

    About Dante Genomics
    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contacts:
    Joshua Resnikoff
    CEO of TMA Precision Health
    info@tmaprecisionhealth.com
    www.tmaprecisionhealth.com

    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com

  • Dante Genomics to innovate universal genomics by now offering easy, at-home blood collection kits for clinical whole genome sequencing without the use of a needle

    Dante Genomics to innovate universal genomics by now offering easy, at-home blood collection kits for clinical whole genome sequencing without the use of a needle

    NEW YORK, September 1, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, announced today that the Company has begun using needleless, at-home blood collection kits for its premium clinical whole genome sequencing test, thus bringing the high quality of concierge clinics to at home testing.

    Dante Genomics is utilizing these at-home blood collection kits for its whole genome sequencing on the www.dantelabs.com website, making it easier than ever and virtually painless for patients to collect their blood sample on their own without having to travel to a hospital or have direct interaction with a mobile phlebotomist. 

    “This groundbreaking innovation comes from our relentless focus on providing universal access to the highest quality genomics technologies,” said Andrea Riposati, CEO of Dante Genomics. “Anyone, anywhere in the world, deserves to receive the most advanced genomic care. Anyone. Anywhere.”

    The collection of blood samples for the use of genomics sequencing has key advantages over the collection of saliva:

    • Saliva-derived DNA contains significantly less DNA than blood-derived DNA.
    • There is far less risk of DNA contamination due to user error.
    • Blood samples have a higher percentage of passing Quality Control standards, avoiding the need for the customer to supply an additional sample to be re-tested.  
    • As a result, blood collection lowers turnaround times significantly for the customer. 

    With this innovation, individuals anywhere in the world get access to the highest quality of genomic testing and now also the best options for sample collection.

    Dante has deployed two products for blood collection: 

    • For the US market, an  FDA registered device that collects whole liquid blood samples that are ready to be used for genomic DNA isolation and sequencing. Users can successfully collect blood samples at home without direct interaction at a lab or with a mobile phlebotomist. 
    • For the European market, a CE-IVD marked device delivers whole dried blood samples from the patient to the lab. Subjects can successfully collect volumetrically precise samples. 

    For our DNA wellness programs and other specific applications, Dante will continue to offer its saliva collection kit as an option.

    About Dante Genomics
    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:
    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com

  • Dante Genomics to Participate in a Panel Presentation at the Canaccord Genuity 42nd Annual Growth Conference

    Dante Genomics to Participate in a Panel Presentation at the Canaccord Genuity 42nd Annual Growth Conference

    NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, today announced that members of its management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, and Andrea Riposati, CEO of Dante Genomics, will participate in a panel presentation on leveraging omics-based data and analytics to advance precision health to the next level on Thursday, August 11, 2022 at 9:30 AM Eastern Time.

    The replay of the panel presentation will be available shortly after the conclusion of the panel discussion on the conference portal for 14 days post event. 

    About Dante Genomics
    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:
    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com

  • Dante Genomics partners with Emirates Post to deliver advanced genomic services in UAE

    Dante Genomics partners with Emirates Post to deliver advanced genomic services in UAE

    The partnership aims to enable universal access to genomic-driven wellness and longevity

    June 22, 2022

    Emirates Post, the official postal operator and leading express provider in the UAE, has partnered with Dante Genomics, a global leader in genomics and precision medicine, to facilitate the availability of advanced genomic services across the UAE in line with the nation’s vision of making healthcare testing accessible to everyone in the country.

    The partnership follows the recent launch of Dante Genomics’ office and operations in the UAE. According to the agreement, Emirates Post will collect and drop off testing kits from Dante Labs to customers across the UAE, in addition to designating Emirates Post Customer Happiness Centers as a point of sale and drop off/collection point for the testing kits. Genetic testing provides personalized information about one’s overall wellbeing to empower them to live a healthier lifestyle.

    Peter Somers, CEO of Emirates Post, said: “We are delighted that Dante Genomics entrusted us to support the expansion of their advanced genomic services across the UAE. This partnership further highlights the seamless services we provide to customers through our delivery network, which is the largest in the country. With its customer-centric and diverse choice of services, Emirates Post is an ideal delivery partner for companies looking for expansion and sustainable solutions to even the remotest parts of the country. Our exemplary services have enabled us to build trust and meet all the requirements of our customers and partners.”

    Andrea Riposati, Group CEO of Dante Genomics, said that universal access to healthcare requires the universal operations that Emirates Posts has built. “Together, we can deliver advanced genomics everywhere. We are honored to partner with Emirates Post on logistics and distribution of advanced genomic services in the UAE. Emirates Post has proven a fantastic partner with a clear vision of how to democratize access to goods, services and technology for all people in the UAE,” he added.

    Dante Genomics is a global leader in genome sequencing with the best technology in the healthcare industry to provide personalized preventive healthcare solutions by offering next-generation diagnostic tools direct to consumers and healthcare professionals. With the use of patented software and revolutionary technologies, including Novaseq 6000 Sequencing System and Pacbio, Dante Labs has achieved unprecedented performance in the field of genetic sequencing. Dante Labs through Novaseq 6000 Sequencing System has recorded an average Passing Filter ratio exceeding 80 per cent on each run performed, proving the lab as top performers within the industry. Passing Filter ratio measures efficiency in genomics.

    -ends-

    About Dante Genomics

    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    About Emirates Post Group

    Emirates Post Group Company is a Public Joint Stock Company under Emirates Investment Authority (EIA) operating as a commercial entity across the emirates. It manages the planning of its postal operational division and subsidiaries, which consist of Emirates Post – the leading postal and express delivery provider in the region, Wall Street Exchange, Instant Cash, and the Electronic Documents Centre. The Dubai-based Company is the official entity responsible for licensing all postal, courier and logistics services within the UAE.

    Contact:

    Laura D’Angelo

    VP of Investor Relations

    ir@dantelabs.com

    +39 0862 191 0671
    www.dantelabs.com

  • Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery

    Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery

    NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases. 

    Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization.

    “Personalized medicine needs personalized data, and our progress in the last 18 months alone demonstrates the value of genomic data to research and discovery drug development,” said Andrea Riposati, CEO of Dante Genomics. “When we founded Dante Genomics, we felt we had a responsibility to deliver personalized medicine beyond diagnosis so that no patient would be facing a diagnosis with no effective treatments. It is this holistic approach that challenges and motivates us as a company to accelerate science to save more lives.”

    Dante has advanced its internal drug programs in muscle rare disease and neurological rare disease into the pre-clinical phase. The newest addition to Dante’s discovery program pipeline is an mRNA oncology therapeutic in the molecular discovery phase meant to strengthen the immune system against certain cancer types. In co-development with US biotechnology company Protelica, Dante has therapies in respiratory disease and ovarian cancer, both in the non-regulatory pre-clinical phase. 

    Dante’s mRNA COVID vaccine program development began in early 2021 and has recently completed the regulatory pre-clinical phase and is ready for its first in-human. 

    “My academic background has taught me the value of RNA therapeutics, and Dante’s internal R&D leverages mRNA and siRNA technology to accelerate time to patients from concept to clinic,” said Mattia Capulli, Chief Scientific Officer of Dante Genomics. “The data and advanced timeline of our mRNA vaccine program demonstrates Dante’s high quality RNA platform and the reproducibility of this model applied to other clinical therapies.

    The Company also announced its rebrand to Dante Genomics to better reflect its global efforts in genomic information and personalized medicine. The company name, Dante Genomics, comes from the compound of humanity and science. “Dante” refers to the Italian humanitarian poet and “Genomics” refers to the powerful science that takes place in a genomics lab. Since its foundation, Dante Genomics has delivered hundreds of thousands of people with affordable, quality genomic solutions to inform their healthcare decisions. The Company’s holistic approach to medicine spans from sequencing and variant interpretation to discovery drug development.

    About Dante Genomics

    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D’Angelo

    VP of Investor Relations

    ir@dantelabs.com

    +39 0862 191 0671

    www.dantegenomics.com

  • Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

    Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
    • Dante Labs is a Global Leader in Genomics and Precision Medicine
    • Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer

    BERKELEY, Calif. and MAINZ, Germany and New York, MAY 19, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC).

    Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals. Inherent to Dante Lab’s business model is managing state-of-the-art genomic sequencing laboratories in multiple international regions, and operating a robust e-commerce platform.

    “As a young company with the goal of bringing to market important diagnostic tools to help treat and prevent cancer indications, it’s an absolute pleasure to partner with an industry leader such as Dante Labs,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Our differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility requires alliances with like-minded companies such as Dante Labs, who share our passion for forward-thinking diagnostic test development and marketing strategies.”

    The partnership will first launch ColoAlert in Italy and UAE using Dante’s various established commercial channels. Samples will initially be processed at Mainz’s in-house facility and then Dante will purchase Mainz’s CE-IVD polymerase chain reaction (PCR) assay kits and transition all test processing to Dante’s wholly-owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) to offer localized service and support.

    “We are excited by the opportunity to align with Mainz and represent ColoAlert in these initial markets,” commented Andrea Riposati, Chief Executive Officer of Dante Labs. “Both the product and the Company mirror our mission to develop and market top-tier preventive health solutions and use new channels to make innovative tests available to more patients around the world. With the launch of our enhanced ecommerce platforms for advanced diagnostics, ColoAlert is an amazing product to deliver more personalized medicine.”

    ColoAlert is currently marketed across Europe, and the partnership with Dante Labs marks the test’s initial launch in the Middle East. Mainz will continue to develop commercial and R&D partnerships with companies that lead the field of health screening with a particular focus on stool diagnostics.

    About ColoAlert

    ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the Europe Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

    *Dollinger MM et al. (2018)

    About Colorectal Cancer

    Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death.  Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US-based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.

    About Mainz Biomed N.V.

    Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

    For more information please visit www.mainzbiomed.com

    For media enquiries, please contact press@mainzbiomed.com

    For investor enquiries, please contact ir@mainzbiomed.com

    About Dante Labs

    Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D’Angelo

    VP of Investor Relations

    ir@dantelabs.com

    +39 0862 191 0671

    www.dantelabs.com

    Forward-Looking Statements

    Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

  • Dante Labs receives grant by Italian government to pilot revolutionary CE-IVD, clinical whole genome sequencing-based Citizen Test for a G7 country, starting a new era in clinical genomics

    Dante Labs receives grant by Italian government to pilot revolutionary CE-IVD, clinical whole genome sequencing-based Citizen Test for a G7 country, starting a new era in clinical genomics

    NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the Italian Ministry of Economic Development has selected Dante to develop and pilot the first fully-CE-IVD, clinically approved whole genome sequencing (WGS) test for the citizens of Italy to be named the Dante Citizen Test. 

    The goal of the project is to introduce clinical whole genome sequencing with clinical reports in the standard medical care of the country’s hospitals and healthcare system and is the first step to introduce whole genome sequencing in the national healthcare system of a European and G7 country. The test will leverage Dante’s proprietary Extensa software for reporting, interpretation and analysis of whole genome and medical data.

    “Clinical whole genome sequencing will finally become a standard solution in public healthcare systems, not as a luxury for the few but as a right for every citizen, thanks to the Dante Citizen Test,” said Andrea Riposati, CEO of Dante Labs. “The effective use of whole genome sequencing in standard clinical care requires mastery at sequencing, interpretation and integration of medical information, at scale. This is what we have been doing at Dante. Now, with partnerships with forward looking governments, like Italy’s, we can impact millions of patients worldwide.”

    The groundbreaking project will be overseen by the Dante’s newly appointed European Medical Genomics Board, which is made of national and multinational world leaders in genomics, including geneticists, molecular biochemists and clinical experts in pharmacogenomics, nutrigenomics and oncogenomics, prenatal, neonatal and pediatric rare diseases.

    About Dante Labs

    Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D’Angelo

    VP of Investor Relations

    ir@dantelabs.com

    +39 0862 191 0671
    www.dantelabs.com

  • Dante selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines

    Dante selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines

    NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the company has been selected as the genetic testing provider for Abu Dhabi Stem Cells Center (ADSCC), the Abu Dhabi based specialist healthcare center focused on cell therapy and regenerative medicine. In parallel, a joint R&D program has been launched focused on the development of a mRNA vaccine platform to identify individual cancer treatments.

    “This collaboration with ADSCC is an important step forward in our strategy to provide the best clinical genetic services now to United Arab Emirates and in the Region. The goal is that partnerships like this will pave the way to a much wider adoption of genomics in additional clinical fields,” said Andrea Riposati, CEO of Dante Labs. “It is clear that the UAE has become a global leader in the field of genomics, and we are pleased to invest in this innovative country.’’

    Effective April 18, 2022, Dante has begun providing clinical genetic testing to ADSCC patients covering a wide spectrum of medical specializations and all testing will take place in Dante’s new Dubai laboratory.

    “We are very excited and are looking forward to our upcoming collaboration with Dante,” said Dr. Yendry Ventura Carmenate, General Manager at ADSCC. “The combined experience of the professionals at the helm of this collaboration gives us absolute assurance in the success of this very ambitious endeavor. Working together with Dante Labs provides us with an excellent opportunity to further boost the status of United Arab Emirates as the worldwide leader in both genomics and innovative healthcare practices, aimed at the eradication of deadly diseases throughout the world for the greater good of humanity.”

    In addition to genomic testing services, Dante and the ADSCC will partner on the launch of an R&D program with a focus on personalized treatments for oncology patients, and eventually the development of cancer vaccines.

    “The hope with testing programs like ours with ADSCC is that it will pave the way for wider adoption of genomes in other areas such as R&D and training programs,” said Professor Mattia Capulli, Chief Scientific Officer of Dante Laboratories. “The mRNA technology is extremely promising for infectious diseases. We are convinced that the joint R&D program will deliver solid results in oncology treatments very soon and will lead to new types of vaccines in oncology and other clinical areas.”

    About Dante Labs

    Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    About Abu Dhabi Stem Cells Center (ADSCC)

    Abu Dhabi Stem Cells Center (ADSCC) is an Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine techniques, as well as delivering cuttingedge research on stem cells in the region. The Center was founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments. Equipped with the latest technologies, medical devices which are unique to the region, and a team of internationally recognized doctors working hand in hand with researchers, ADSCC is the first of its kind in the UAE. The Center focuses primarily on harvesting, processing, characterizing and storing cell products for clinical application in both regenerative medicine and hematopoietic transplantation. It aims to streamline and develop new processes related to stem cell therapy and research, in order to both serve our team of doctors’ clinical needs and become a referral center for the region.

    Contacts:

    Laura D’Angelo

    VP of Investor Relations

    ir@dantelabs.com

    +39 0862 191 0671

    http://www.dantelabs.com

    info@adscc.ae

    Abu Dhabi Stem Cells Center

  • Dante Labs announces ventures into biosimulation and drug discovery, demonstrating the predictive value of the Dante Platform

    Dante Labs announces ventures into biosimulation and drug discovery, demonstrating the predictive value of the Dante Platform

    APRIL 11, 2022

    NEW YORK, April. 11, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomic information and precision medicine, announces new genomic driven biosimulation and significant progress made to its drug discovery program, demonstrating the value of the Dante Platform. 

    “Often the first concern from patients after they receive a diagnosis through whole genome sequencing is what therapies are available to treat their condition. In an effort to address this issue, Dante Labs decided to create and invest in a drug discovery R&D program,” said Andrea Riposati, CEO of Dante Labs. “We are uniquely positioned to deliver more complete medical solutions from whole genome sequencing and diagnosis through drug discovery and the development of therapies for patients.” 

    Dante’s integrated approach to data, software and AI has enabled the Company to develop a biosimulation platform based on Dante’s database of genomic and medical data. The platform predicts changes in viruses and is being used by Dante to simulate future variants of the SARS-CoV2 virus responsible for COVID-19. Dante has an existing patent portfolio surrounding its mRNA and iRNA technology and continues to invest and develop additional patents.

    Dante’s venture into biosimulation, which is anchored in whole genome sequencing data,  supports the development of therapies and drugs, delivering a more personalized, holistic approach to medicine. This computational approach to the design of new drug programs is foundational to the Company’s efforts to deliver end-to-end solutions to people for which there are currently limited or no therapies to treat their conditions. 

    Since its foundation, Dante has financed a broad R&D program with the aim to create the first end-to-end solution from diagnosis to therapy with a strong focus on rare diseases and with the ambition to export the model to other disease areas like cancer in the near future. In the past two quarters alone, Dante Labs has advanced its drug programs in muscle rare disease, neurological rare disease and immunology into the pre-clinical phase. Additionally, Dante has launched four new drug programs in co-development with external partners in COVID, oncology and degenerative disease. 

    About Dante Labs

    Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D’Angelo

    VP of Investor Relations

    ir@dantelabs.com

    +39 0862 191 0671
    www.dantelabs.com

  • Does our genetic make-up influence our personality?

    Does our genetic make-up influence our personality?

    APRIL 6, 2022

    The influence of our genes on our personalities is a fascinating and hotly debated subject in psychology. It’s a question of nature versus nurture – a phrase was coined in 1969 by Psychologist Sir Francis Galton who used it to describe the impact of genes versus environmental influences. Our physical appearance and our health are undeniably influenced by both. We can inherit blonde curly hair and blue eyes from either parents (nature) and our environment, whether it’s a polluted city or a seaside town, can impact our respiratory health in the long term (nurture). But can the same logic be applied to our personalities? 

    Genes are around 99% the same in each human being. These common genetic structures mean that members of the same species have behaviours and characteristics that define them – known as instincts. These complex yet innate patterns of behaviour ensure survival and reproduction. Birds sing at daybreak, rabbits burrow in the ground and humans learn to walk, speak and understand language. But the strength of traits between species varies. Some rabbits are more fearful than others, some dogs like to lie in on the weekend, and others are driven to chase sticks around at 100mph. These differences occur in humans too – the 0.1% difference in genes produces a unique set of traits and characteristics that make human beings the individuals that they are. 

    But do we inherit all our characteristics from our parents, or do we change in response to the way that we live our lives? If we look at the argument for nature, it suggests that our personalities form early in our lives and are difficult to change. If we argue for nurture, then it’s our experiences that are important, suggesting that our personalities evolve as time goes on. 

    Some geneticists estimate that as much as 60% of our personality is determined by genes. However, there is no IQ gene that determines intelligence, no kindness gene that determines whether a child will bully another. But rather there is a complex relationship among the various genes. Some genes work to increase characteristics, and others will decrease those same characteristics. The largest breakthrough in genetic research the past few years is polygenic testing. This is able to correlate multiple genes – often thousands – with behaviour differences. Using polygenic testing, we can identify genes such as great leadership quality, vulnerability to stress and nervousness and even distractibility. 

    Genetic factors also always work in tangent with environmental factors. For example, our upbringing, culture, geography and life experience can all greatly influence our personality. For example, one study into regional personality types in America identified three clusters:

    • Cluster 1: The Upper Midwest and Deep South were associated with personality types that comprised people of a “friendly and conventional nature.”
    • Cluster 2: The West is mainly comprised of people who were relaxed, creative, calm, and emotionally stable
    • Cluster 3: The Northeast was mainly comprised of people who are people who were exposed to stress and therefore more likely to experience irritableness or depression

    However, extent to which we are influenced by our biology is disputed. A number of large-scale twin studies suggest that we are largely determined by our biology and not our environment. The Minnesota Study of Twins Reared Apart studied 350 pairs of twins between 1979 and 1999. The results revealed that the personalities of twins, whether they were raised separately of apart, displayed similar personality traits to their biological parents. 

    The nature versus nurture argument is certainly rich and complex, and always ongoing. If you want to learn more about how your genetic makeup influences your personality, our Whole Genome Test can reveal all. 
    Click the link to find out more: https://dantelabs.com/products/whole-genome-sequencing